With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
EGFR appears to be this year’s white whale of GI cancer. We already talked about the negative results of adding cetuximab (an EGFR monoclonal antibody) to chemoradiation for esophageal cancer. Now results of the CONKO-005 trialassessing adjuvant gemcitabine +/- erlotinib (an EGFR tyrosine kinase inhibitor) in patients with completely resected pancreatic cancer adds waves to the storm: Adding erlotinib improved neither survival nor disease control. Over half of patients recurred within a year, with a median survival of just over two years. This is sobering news for a rare pancreatic cancer population (with margin-negative resections) for whom we should expect the best possible outcomes. Too bad this trial didn’t have an adaptive design, which may need to be the next sail we cast among these less common GI cancers in our search for substantial survival outcomes that as of yet remain elusive.